The estimated Net Worth of Lawrence Otto Klein is at least $20.2 Million dollars as of 10 March 2022. Lawrence Klein owns over 7,584 units of CRISPR Therapeutics AG stock worth over $1,273,501 and over the last 6 years he sold CRSP stock worth over $12,805,000. In addition, he makes $6,112,840 as Chief Operating Officer and Chief Business Officer at CRISPR Therapeutics AG.
Lawrence has made over 9 trades of the CRISPR Therapeutics AG stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 7,584 units of CRSP stock worth $344,617 on 10 March 2022.
The largest trade he's ever made was selling 100,000 units of CRISPR Therapeutics AG stock on 23 March 2021 worth over $12,805,000. On average, Lawrence trades about 12,558 units every 42 days since 2019. As of 10 March 2022 he still owns at least 28,026 units of CRISPR Therapeutics AG stock.
You can see the complete history of Lawrence Klein stock trades at the bottom of the page.
Dr. Lawrence Otto Klein Ph.D. serves as Chief Operating Officer, Chief Business Officer of the Company. Dr. Klein has served as our Chief Business Officer since January 2019; before that, Dr. Klein served as our Senior Vice President, Business Development and Strategy from November 2017 to December 2018 and as our Vice President, Strategy from February 2016 to October 2017. Before joining our company, from October 2014 to February 2016, Dr. Klein was an Associate Partner at McKinsey & Company, where he was a leader in the biotech practice and served a number of biotechnology companies on a wide range of topics from strategy to operations. Dr. Klein received a Ph.D. from Stanford University, where he conducted research in the field of T cell immunology, and he holds a B.S. from the University of Wisconsin at Madison.
As the Chief Operating Officer and Chief Business Officer of CRISPR Therapeutics AG, the total compensation of Lawrence Klein at CRISPR Therapeutics AG is $6,112,840. There are 1 executives at CRISPR Therapeutics AG getting paid more, with Samarth Kulkarni having the highest compensation of $16,265,700.
Lawrence Klein is 37, he's been the Chief Operating Officer and Chief Business Officer of CRISPR Therapeutics AG since 2020. There are 15 older and no younger executives at CRISPR Therapeutics AG. The oldest executive at CRISPR Therapeutics AG is Katherine High, 68, who is the Independent Director.
Lawrence's mailing address filed with the SEC is 610 Main St, Cambridge, MA 02139, USA.
Over the last 8 years, insiders at CRISPR Therapeutics AG have traded over $284,003,967 worth of CRISPR Therapeutics AG stock and bought 3,347,446 units worth $53,410,590 . The most active insiders traders include Plc Gsk, Ali Behbahani, and Corp /De/ Celgene. On average, CRISPR Therapeutics AG executives and independent directors trade stock every 13 days with the average trade being worth of $2,405,548. The most recent stock trade was executed by Julianne Bruno on 20 June 2024, trading 7,000 units of CRSP stock currently worth $318,080.
CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.
CRISPR Therapeutics AG executives and other stock owners filed with the SEC include: